(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of relapsed / refractory Non Hodgkin's Lymphoma. Rituximab to be included in CD20 positive patients. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | CD20 + | Non-Hodgkin Lymphoma | Carboplatin, Etoposide, Ifosfamide, Rituximab |